PADI4 and autoimmune disease: Importantly, several groups of researchers have provided evidence that NET release is dramatically impaired by the genetic deficiency (35) or the pharmacological inhibition of PAD4 (36), and that PAD4 inhibitors offer promising starting points to develop autoimmune disease therapies (37, 38).